In this article, we will look at the 5 Stocks Making Huge Moves this Week. For a deeper discussion and an extended list, please see 10 Stocks Making Huge Moves this Week.
Photo by Tima Miroshnichenko on Pexels
5. Sasol Ltd. (NYSE:SSL)
Sasol Ltd. soared by 26.2 percent week-on-week, hitting an over two-year high on Friday, as investors took heart from JPMorgan’s 122-percent price target upgrade for its stock.
In Friday’s session alone, Sasol Ltd. (NYSE:SSL) hit its highest price of $11.51 before trimming gains to end the session just up by 6.70 percent at $11.31 apiece.
This followed JPMorgan’s rating upgrade for Sasol Ltd. (NYSE:SSL) to “overweight” from “underweight” previously, while issuing a new price target of 209 rand, or a 122 percent boost from 94 rand previously.
The coverage was based on its optimism that Sasol Ltd. (NYSE:SSL) would benefit from higher oil prices and supply disruptions amid ongoing tensions in the Middle East.
According to JPMorgan, its global commodities unit expects oil production cuts of 12 million barrels per day (bpd) in seven days, and further to 16 million bpd in the next 14 days. The Middle East and North Africa regions have already slashed production of approximately 5.5 million bpd.
Additionally, JPMorgan expects benchmark crude oil prices to jump to $120 per barrel and further to $250 if the Strait of Hormuz—a critical waterway where 20 percent of the global oil supply passes through—closes for six months.
4. Nebius Group NV (NASDAQ:NBIS)
Nebius Group soared by 26.4 percent week-on-week, as investors mirrored Nvidia Corp.’s backing of the company through the acquisition of a $2 billion stake.
In a statement, Nvidia said that the total investment complements a partnership recently sealed with Nebius Group NV (NASDAQ:NBIS) for the joint development and deployment of next-generation hyperscale cloud for the AI market.
Under the agreement, the two firms would collaborate on AI factory design and support, including access to partner design material, design review process and acceptance, and regular business and technical reviews, among others.
They would also partner on creating a best-in-class inference and agentic AI stack for developers and enterprises with Nvidia’s latest software technologies, optimized models, and libraries.
Nebius Group NV (NASDAQ:NBIS) would deploy multiple generations of Nvidia’s infrastructure across its platform, as well as the latest GPU health monitoring to allow software recommendations.
At present, Nebius Group NV (NASDAQ:NBIS) is underway with the development of an AI factory capable of powering 5 GW of capacity. Deployment is expected to start over the next four years.
3. Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Xenon Pharmaceuticals climbed by 31.7 percent week-on-week, as investor sentiment was bolstered by positive clinical trial for its epilepsy and depression treatment candidate, alongside plans to submit a new drug application (NDA) in the second half of the year.
In a statement earlier in the week, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said that it would submit an NDA for its treatment candidate, Azetukalner, with the Food and Drug Administration (FDA) in the third quarter.
This followed the completion of the third phase of clinical trial, which saw a 53 percent seizure reduction in patients who took both 25mg and 15mg, versus the placebo, over a 12-week period.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) added that Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies.
“We are very happy to announce these data for azetukalner, which exceeded expectations and, to our knowledge, show the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study,” Xenon Pharmaceuticals Inc. (NASDAQ:XENE) President and CEO Ian Mortimer said.
Following the results, the company successfully raised $747.5 million in fresh funds from a public offering of 12.2 million common shares.
2. AXT Inc. (NASDAQ:AXTI)
AXT Inc. soared by 50.9 percent week-on-week, as investors continued to hunt for technology stocks while shifting away from sectors seen as more vulnerable to the ongoing tensions in the Middle East.
Month-to-date, AXT Inc. (NASDAQ:AXTI) has notably climbed by as much as 37 percent, even hitting an all-time high of $51.98 on Friday.
The rally can also be attributed to strong investor confidence after the company posted a highly optimistic outlook for the first quarter of the year amid expected progress on its export permits.
“While we are disappointed that we didn’t receive as many export permits in Q4 as we had hoped, we are pleased to report that we have received some permits to date in 2026 and believe we are in a strong position to achieve sequential revenue growth in Q1, driven primarily by growth in indium phosphide for the AI infrastructure build-out,” AXT Inc. (NASDAQ:AXTI) CEO Morris Young said earlier.
“We are also on track to double our indium phosphide manufacturing capacity this year and have a strong balance sheet to support our continued business expansion,” he noted.
Last year, AXT Inc. (NASDAQ:AXTI) widened its attributable net loss by 83 percent to $21.26 million from $11.6 million in 2024. Revenues also declined by 11 percent to $88 million from $99 million year-on-year.
In the fourth quarter alone, attributable net loss narrowed by 31 percent to $3.5 million from $5.09 million, while revenues dropped by 8 percent to $23 million from $25 million.
1. Hims & Hers Health Inc. (NYSE:HIMS)
Hims & Hers saw its share prices jump by 57.4 percent week-on-week, with the rally primarily driven by its renewed partnership with Novo Nordisk, as well as analysts’ upgraded price targets for its stock.
In a statement, Hims & Hers Health Inc. (NYSE:HIMS) said that it clinched a new partnership with Novo for a new strategy that would do away with the sale of its compounded versions of the latter’s blockbuster drugs, Wegovy and Ozempic.
Hims & Hers Health Inc. (NYSE:HIMS) said that it would only offer access to its own GLP-1 in cases where the needs of the customers cannot be met using the FDA-approved version, and if a provider determines that a compounded product is clinically necessary.
Following the news, the company earned upgraded price targets and ratings from three investment companies, namely Deutsche Bank, Citigroup, and Bank of America (BofA).
For its part, Deutsche Bank raised its target to $28 from $25 previously, and maintained a “neutral” stance, while Citigroup issued a $24 price target, an improvement from the $13.25 prior.
BofA, on the other hand, gave a $23 price target, markedly higher than the $12.50 previously.
Citigroup and BofA both upgraded their ratings to “neutral” from “sell” and “underperform,” respectively.
While we acknowledge the potential of HIMS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HIMS and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
